Skip to main content

Capricor Therapeutics, Inc.

corporate_fare Company Profile

Capricor Therapeutics, Inc.

CAPR·NASDAQ·Life Sciences·CIK 0001133869

Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially selling cell and exosome-based treatments. The company primarily targets Duchenne muscular dystrophy ("DMD"), a rare genetic disorder causing progressive muscle degeneration and early death, along with other diseases where current treatments are insufficient. Since its start, the company has invested heavily in its main product candidate, Deramiocel, a cell therapy designed to address heart and skeletal muscle issues related to DMD. They have also advanced their exosome-based technology, built manufacturing capabilities, and supported research and development. The U.S. Food and Drug Administration ("FDA") is currently reviewing Capricor Therapeutics' Biologics License Application ("BLA") for Deramiocel to treat DMD. The FDA's target date for action, under the Prescription Drug User Fee Act ("PDUFA"), is August 22, 2026, for potential approval in the United States. The company currently has no products approved for commercial sale. If approved, Capricor Therapeutics plans to sell Deramiocel in the United States and may partner with other companies for sales in specific international markets. Deramiocel's development for DMD has involved multiple clinical studies, and the company continues activities to support regulatory review, potential U.S. approval, and commercialization preparations. Their core program centers on Deramiocel, a cell therapy made from cardiosphere-derived cells ("CDCs"). These CDCs are a type of cardiac stromal cell obtained from donated human hearts and are intended to treat Duchenne muscular dystrophy. Deramiocel aims to slow disease progression through the CDCs' ability to modulate the immune system, reduce inflammation, promote blood vessel formation, and prevent fibrosis. These effects are partly due to exosomes released by CDCs, which contain active molecules like microRNAs and other signaling factors that can affect gene expression and cellular processes involved in inflammation, fibrosis, and tissue repair.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for CAPR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-21, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 12 rated 8 or above. Recent SEC coverage for CAPR spans 10-Q, 8-K.

Recent high-impact activity:

  • Capricor Weighs Cost Cuts After Second FDA Rejection of Deramiocel
  • FDA Rejects Capricor's Duchenne Cell Therapy, Deramiocel
  • Deramiocel Meets Phase 3 HOPE-3 Primary Endpoint, But Cardiac Data Miss
  • Capricor Q3 Loss Widens to $42.7M; Cash Falls to $198.5M Ahead of Nov 22 PDUFA
  • Capricor Posts Wider Q3 Loss of 73 Cents, Zero Revenue vs $41.7M Expected

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$105.04M
Diluted EPS
-$2.26
Op. Cash Flow
-$69.81M
Free Cash Flow
-$72.72M
Operating Income
-$108.14M
Cash & Equivalents
$287.85M
Debt / Equity
0.00×
Shares Outstanding
57.37M sh
Source: 10-K · filed 2026-03-17 · accession 0001104659-26-029580

Short Interest & Short Volume

7.38 days to cover

FINRA reported short interest of 18,765,089 shares in CAPR as of the October 30, 2026 settlement, a 5.5% decrease from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 65.0% of CAPR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,765,089 shares as of October 30, 2026
Change vs prior period▼ 5.5%
Days to cover7.38 at avg daily volume of 2,541,920
Daily short volume (FINRA facilities)65.0% of 4,484,469 shares on November 20, 2026
5-day average short volume62.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$1.65 -78.33% today
52-week range · as of 2026-11-10 $1.65 – $40.37
Market cap
$441.3M
Volume
20.1M (4.4× avg)
3-mo avg 4.6M
Live data · 2026-11-21 23:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CAPR - Latest Insights

CAPR
Nov 21, 2026, 7:25 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $1.65 info
Change: $0 (0%) info
Market Cap: $441.299M info
CAPR
Nov 20, 2026, 6:36 PM EST
Source: Reuters
Importance Score:
10
Updated Nov 20, 10:52 PM ET — The complete response letter said available data did not provide substantial evidence of efficacy and cited serious deficiencies in the der…
Price at Filing: $2.12
Real-time Price: $1.65 info
Change: -$0.475 (-22%) info
Market Cap: $441.299M info
CAPR
Nov 18, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $1.65 info
Change: -$7.13 (-81%) info
Market Cap: $441.299M info
CAPR
Nov 10, 2026, 5:25 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $1.65 info
Change: -$7.71 (-82%) info
Market Cap: $441.299M info
CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $1.65 info
Change: -$7.46 (-82%) info
Market Cap: $441.299M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $1.65 info
Change: -$7.26 (-82%) info
Market Cap: $441.299M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $1.65 info
Change: -$7.44 (-82%) info
Market Cap: $441.299M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $1.65 info
Change: -$6.58 (-80%) info
Market Cap: $441.299M info
CAPR
Sep 29, 2026, 9:24 PM EDT
Source: Seeking Alpha
Importance Score:
8
Updated Oct 5, 9:11 AM ET — Placebo crossover patients' upper limb decline slowed 76% in their first year on deramiocel; both groups declined slower than natural histo…
Price at Filing: $10.27
Real-time Price: $1.65 info
Change: -$8.63 (-84%) info
Market Cap: $441.299M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $1.65 info
Change: -$5.24 (-76%) info
Market Cap: $441.299M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $1.65 info
Change: -$5.24 (-76%) info
Market Cap: $441.299M info
CAPR
Aug 21, 2026, 1:47 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $6.12
Real-time Price: $1.65 info
Change: -$4.48 (-73%) info
Market Cap: $441.299M info
CAPR
Aug 18, 2026, 6:17 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.31
Real-time Price: $1.65 info
Change: -$5.66 (-77%) info
Market Cap: $441.299M info
CAPR
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $6.69
Real-time Price: $1.65 info
Change: -$5.05 (-75%) info
Market Cap: $441.299M info
CAPR
Aug 14, 2026, 4:46 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.58
Real-time Price: $1.65 info
Change: -$4.93 (-75%) info
Market Cap: $441.299M info
CAPR
Aug 14, 2026, 6:33 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.15
Real-time Price: $1.65 info
Change: -$7.51 (-82%) info
Market Cap: $441.299M info
CAPR
Aug 14, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.04
Real-time Price: $1.65 info
Change: -$5.40 (-77%) info
Market Cap: $441.299M info
CAPR
Aug 13, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.82
Real-time Price: $1.65 info
Change: -$3.18 (-66%) info
Market Cap: $441.299M info
CAPR
Aug 04, 2026, 6:36 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $1.65 info
Change: -$2.49 (-60%) info
Market Cap: $441.299M info
CAPR
Jul 30, 2026, 8:02 AM EDT
Source: Reuters
Importance Score:
10
Price at Filing: $2.88
Real-time Price: $1.65 info
Change: -$1.24 (-43%) info
Market Cap: $441.299M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets